Long term follow-up of patients with chronic hepatitis C treated with interferon alpha. 2000

J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
Department of Medicine, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

Interferon alpha (IFN alpha) treatment for chronic hepatitis C induces a sustained biochemical and virological response at six months after completing 24 weeks of therapy in approximately 10% of patients. The long term durability of this 'sustained' response is still controversial. The aim of this multicentre study was to assess the long term virological response in patients considered to have achieved a sustained biochemical response six months after completing IFN treatment. The majority (36 of 41) of the sustained responders identified had been treated for six months with IFN therapy. Twenty-nine of the 41 patients (70%) had undetectable hepatitis C virus (HCV) RNA after a mean follow-up of 38 months after cessation of treatment (range six to 92 months). All but one of those 29 individuals had normal serum alanine aminotransferase (ALT) levels. Of the 16 patients (out of 41) who had been tested for HCV RNA six months after treatment, HCV RNA remained undetectable in 14 (88%) at final follow-up. Serum ALT values in the 11 of 12 patients whose HCV RNA was positive at final follow-up were lower than pretreatment values, and in six cases were within the normal range. The long term sustained virological response in those considered a 'sustained responder' six months after receiving only six months of IFN is high. Measurement of ALT is an unreliable marker of sustained response to therapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA

Related Publications

J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
June 1992, Hepatology (Baltimore, Md.),
J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
January 1996, Digestion,
J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
December 1993, Hepatology (Baltimore, Md.),
J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
August 2005, International journal of molecular medicine,
J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
June 1994, Hepatology (Baltimore, Md.),
J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
May 1999, Journal of hepatology,
J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
December 1993, Gastroenterology,
J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
January 1999, Hepato-gastroenterology,
J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
November 1997, Gastroenterology,
J D Collier, and P A Adams, and V Feinman, and C Ghent, and H Witt-Sullivan, and G Minuk, and M Krajden, and J Heathcote
August 1994, Zeitschrift fur Gastroenterologie,
Copied contents to your clipboard!